Your browser doesn't support javascript.
loading
Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial.
Stebbing, Justin; Baranau, Yauheni; Baryash, Valery; Moiseyenko, Vladimir; Boliukh, Dmytro; Antone, Nicoleta; Manikhas, Alexey; Chornobai, Anatolii; Park, Taehong; Baek, Eric Hyungseok; Lee, Jaeyong; Choi, Jiin; Kim, Nahyun; Ahn, Keumyoung; Lee, Sang Joon; Kim, Sunghyun.
Afiliação
  • Stebbing J; Department of Surgery and Cancer, Imperial College London, London, UK.
  • Baranau Y; School of Life Sciences, Anglia Ruskin University, Cambridge, UK.
  • Baryash V; Oncogene, London, UK.
  • Moiseyenko V; Chemotherapy Department 1, Minsk City Clinical Cancer Center, Minsk, Belarus.
  • Boliukh D; Chemotherapy Department 1, Minsk City Clinical Cancer Center, Minsk, Belarus.
  • Antone N; Oncology Department, St. Petersburg Clinical Scientific and Practical Centre of Specialized Kinds of Medical Care, St. Petersburg, Russian Federation.
  • Manikhas A; Chemotherapy Department, Vinnytsya Regional Clinical Oncology Dispensary, Vinnytsya, Ukraine.
  • Chornobai A; Radiotherapy I Department, IOCN-The Oncology Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania.
  • Park T; Oncology Department, City Clinical Oncological Dispensary, St. Petersburg, Russian Federation.
  • Baek EH; Chemotherapy Department, Poltava Regional Clinical Oncology Center, Poltava, Ukraine.
  • Lee J; Clinical Planning, Celltrion, Inc., Incheon, Republic of Korea.
  • Choi J; Clinical Planning, Celltrion, Inc., Incheon, Republic of Korea.
  • Kim N; Biometrics, Celltrion, Inc., Incheon, Republic of Korea.
  • Ahn K; Biometrics, Celltrion, Inc., Incheon, Republic of Korea.
  • Lee SJ; Biometrics, Celltrion, Inc., Incheon, Republic of Korea.
  • Kim S; Clinical Planning, Celltrion, Inc., Incheon, Republic of Korea.
BioDrugs ; 37(3): 433-440, 2023 May.
Article em En | MEDLINE | ID: mdl-36881323
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Problema de saúde: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Assunto principal: Neoplasias da Mama / Medicamentos Biossimilares Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: BioDrugs Assunto da revista: ALERGIA E IMUNOLOGIA / GENETICA MEDICA / TERAPEUTICA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Problema de saúde: 1_doencas_nao_transmissiveis / 2_muertes_prematuras_enfermedades_notrasmisibles Assunto principal: Neoplasias da Mama / Medicamentos Biossimilares Tipo de estudo: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: BioDrugs Assunto da revista: ALERGIA E IMUNOLOGIA / GENETICA MEDICA / TERAPEUTICA / TERAPIA POR MEDICAMENTOS Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Reino Unido